Rezolute, Inc. (NASDAQ: RZLT) met with the U.S. Food and Drug Administration (FDA) on March 17 2026 to review the results of its Phase 3 sunRIZE trial for congenital hyperinsulinism. The company reported clinically meaningful reductions in hypoglycemia events and time spent in hypoglycemia, but the primary endpoint did not reach statistical significance.
The trial’s primary endpoint miss was attributed to behavioral factors that can confound self‑monitored glucose data, including unblinded patient and caregiver perceptions and the inherent limitations of self‑monitored blood glucose metrics in this rare disease population. Despite the statistical miss, the data set includes favorable secondary outcomes and preliminary observations from an open‑label extension that show continued improvement in glycemic control and a reduction in background therapies.
During the meeting, the FDA acknowledged the challenges posed by these behavioral factors and encouraged Rezolute to submit the full study reports and analysis datasets for independent evaluation. The agency’s response indicates that the drug candidate, ersodetug, is not being dismissed outright, keeping a potential regulatory pathway open pending the review of the submitted data.
CEO Nevan Charles Elam said, "We are extremely encouraged by the outcome of our meeting with FDA including the fact that, while acknowledging their feedback was preliminary, the agency did not dismiss sunRIZE outright on the basis of not meeting its primary endpoint." Chief Medical Officer Brian Roberts added, "We are disappointed that the study did not demonstrate significant improvements in glucose‑related endpoints relative to placebo as well as for the patients and families living with congenital HI who urgently need new treatment options."
The FDA’s willingness to continue the dialogue and request additional data underscores the agency’s recognition of the trial’s complexities and the potential value of ersodetug. The next steps involve Rezolute’s submission of the full data package, after which the company will assess whether the evidence supports a marketing application or if further information is required.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.